Timely reperfusion therapy with either fibrinolysis or primary percutaneous coronary intervention (PCI) is recommended for patients with ST-segment elevation myocardial infarction (STEMI).
1 However, agreeing on the definition of “timely” is difficult, because the benefit achieved by earlier initiation of reperfusion therapy is controversial. The only unbiased studies that have evaluated the effects of earlier reperfusion therapy on outcome are randomized controlled studies that compared prehospital and in-hospital fibrinolysis. In those studies, prehospital fibrinolysis was associated with earlier initiation (1 hour) of reperfusion therapy, resulting in an extra 15 to 21 lives saved per 1000 treated patients.
2-4 The time-dependent benefit of primary PCI has been evaluated from observational data only, and the nearly neutral relationship observed between treatment delay and mortality may lead to the perception that the effect of primary PCI is less time-dependent than the effect of fibrinolysis.
5-7